Spectrum Pharmaceuticals, Inc
83
1
2
42
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
43.4%
36 terminated/withdrawn out of 83 trials
53.8%
-32.7% vs industry average
23%
19 trials in Phase 3/4
93%
39 of 42 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (83)
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
Role: lead
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Role: lead
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
Role: collaborator
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
Role: collaborator
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Role: collaborator
OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
Role: collaborator
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Role: lead
Study of Poziotinib in Japanese Patients With NSCLC
Role: lead
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Role: lead
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
Role: lead
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Role: lead
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Role: collaborator
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
Role: collaborator
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Role: collaborator
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma
Role: collaborator
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Role: collaborator
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Role: collaborator
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Role: lead
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
Role: lead
Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
Role: lead